Phase I/II Study of Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients with Acute Spinal Cord Injury: A Double-Blind, Randomized Clinical Trial of Safety and Efficacy

• Published in: Journal of neurotrauma Vol. 37; no. 15; pp. 1752 - 1758
• Main Authors: Nagoshi, Narihito, Tsuji, Osahiko, Kitamura, Kazuya, Suda, Kota, Maeda, Takeshi, Yato, Yoshiyuki, Abe, Takayuki, Hayata, Daichika, Matsumoto, Morio, Okano, Hideyuki, Nakamura, Masaya
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.08.2020
• Subjects: Amyotrophic lateral sclerosis; Analysis of covariance; Animal models; Blindness; Clinical trials; Disease; Double-blind studies; Drug dosages; Growth factors; Hepatocyte growth factor; Informed consent; Patients; Registration; Spinal cord injuries; Standard deviation; Studies; clinical trial; SCI; hepatocyte growth factor

Spinal cord injury (SCI) is an abrupt traumatic injury that leads to permanent functional loss, and no practical treatment is available. We have developed pharmaceutical recombinant human hepatocyte growth factor (KP-100), and its efficacy for SCI has been verified using animal models. The purpose o...